jinghui xie | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Mr. jinghui xie | Molecular Biology | Best Researcher Award 

Associate professor, at xinjiang medical university, China.

Dr. Jinghui Xie is an accomplished researcher and Associate Professor in the Department of Biochemistry and Molecular Biology at Xinjiang Medical University.  He holds a Doctor of Science (Ph.D.) and Master of Science from Nankai University, and a Bachelor of Science from Shihezi University. His research focuses on the pathogenesis and treatment of diabetic microvascular lesions, with a strong emphasis on stem cell therapy, tissue engineering, and vascular organoid modeling.  Dr. Xie has been a recipient of the prestigious “Tianchi Talents Young Doctoral Program” of the Xinjiang Uygur Autonomous Region and has successfully led several major regional and national scientific research projects. 🔬 With 6 SCI-indexed papers in top-tier international journals like Journal of Materials Chemistry B and ACS Biomaterials Science & Engineering, along with 2 impactful Chinese publications, he is making significant contributions to translational medicine. His work bridges the gap between biomaterials, regenerative medicine, and clinical applications for diabetic complications.

Professional Profile

Google Scholar

🎓 Education

Dr. Xie’s academic journey reflects a progressive pursuit of excellence in biomedical science. 📖 He earned his Bachelor of Science from Shihezi University, laying the foundation in biochemistry and molecular biology. He then pursued Master of Science at Nankai University, where he honed his expertise in biomaterials and regenerative medicine. 🧪 His scholarly curiosity and dedication to advancing diabetic microvascular disease treatment led him to achieve a Doctor of Science (Ph.D.) in Biochemistry and Molecular Biology at Nankai University. During his Ph.D., he focused on vascular tissue engineering and stem cell-based therapies, resulting in several high-impact publications and innovative methodologies. 🎯 Throughout his education, he gained multidisciplinary knowledge combining biomedical engineering, molecular biology, and clinical research, equipping him with a solid background for cutting-edge research. 🎓💡

💼 Experience

Dr. Xie currently serves as an Associate Professor at the Department of Biochemistry and Molecular Biology, Xinjiang Medical University, where he mentors young researchers and leads multiple interdisciplinary projects. 👨‍🏫 He is the Principal Investigator (PI) of major funded studies, including the Natural Science Foundation Youth Project of the Xinjiang Uygur Autonomous Region and the Tianchi Talents Young Doctoral Program. 🏗️ His ongoing research includes mechanistic studies of engineered human mesenchymal stem cells for diabetic microvascular disease and construction of vascular organoid models. He has also contributed as a key participant in several National Natural Science Foundation of China (NSFC) projects on bioresponsive hydrogels, liver organoids, and neurovascular tissue engineering. 🔬 Beyond research, Dr. Xie actively contributes to academic development through teaching, curriculum improvement, and editorial roles in medical education journals. 🏅

🔬 Research Interests

Dr. Xie’s research is deeply rooted in regenerative medicine, biomaterials, and vascular biology. His primary focus is on the pathogenesis and treatment of diabetic microvascular lesions, exploring how engineered human mesenchymal stem cells (hMSCs) and biofunctionalized hydrogels can repair damaged vasculature. 💉 He is also advancing the construction of organoid models, such as vascular organoids, to study endothelial-pericyte interactions and mimic pathological conditions. 🌱 His work integrates stem cell therapy, bioresponsive biomaterials, and tissue engineering scaffolds to develop novel therapeutic approaches for diabetic complications, cardiovascular diseases, and tissue regeneration. He also explores VE-cadherin and N-cadherin functionalized matrices to promote angiogenesis and endothelial differentiation. 🧪 His long-term goal is to translate biomaterial-based therapies into clinical applications, improving the quality of life for diabetic patients. 🌟

🏆 Awards & Honors

Dr. Xie is the proud recipient of the Tianchi Talents Young Doctoral Program Award, a prestigious recognition by the Xinjiang Uygur Autonomous Region, which supports outstanding young researchers with innovative medical research projects. 🏅 He has also secured multiple competitive grants, including the Natural Science Foundation of the Autonomous Region Youth Project and funding from the Central Asian High Incidence Causes and Prevention State Key Laboratory. 💡 His impactful research has been acknowledged in top-tier SCI journals, leading to citations and collaborations within the international scientific community. 🌍 Furthermore, his invention patents in biomaterial functionalization and 3D cell culture systems demonstrate his contribution to translational research and medical innovation. 🚀

📚 Top Noted Publications 

Dr. Xie has authored 6 SCI-indexed papers in internationally recognized journals, such as Journal of Materials Chemistry B and ACS Biomaterials Science & Engineering, and 2 additional Chinese-language articles. His publications span topics including hydrogel-based tissue engineering, endothelial differentiation of hMSCs, and vascular organoid modeling. 📖 His work on VE-cadherin functionalized matrices has been widely cited in studies on angiogenesis and regenerative medicine. ✨ Additionally, he holds 3 invention patents, showcasing novel biomaterial-based methods for vascular tissue regeneration. His research contributions have been cited in applied biomaterials, cardiovascular therapy, and diabetes-related tissue engineering studies, reinforcing his influence in the field. 🌐

🔗 Representative Publications with Citation Prompt

📄 1️⃣ Lv C, Li S, Sang M, Cui T, Xie J.
Title: Construction of Microsphere Culture System for Human Mesenchymal Stem Cell Aggregates
Journal: International Journal of Molecular Sciences
Year: 2025, Volume 26, Article 6435
Link: 🔗 Read Here
Citation Context: Frequently cited in organoid culture system research for its innovative approach to MSC aggregate formation.

📄 2️⃣ Jinghui Xie, Xiaoning Li, Yan Zhang, et al.
Title: VE-Cadherin based matrix promoting self-reconstruction of proangiogenic microenvironment
Journal: Journal of Materials Chemistry B
Year: 2021, 9(1), pp. 3357–3370
Link: 🔗 Read Here
Citation Context: Referenced in endothelial differentiation studies exploring angiogenic microenvironments.

📄 3️⃣ Yuanning Lyu, Jinghui Xie, Yang Liu, et al.
Title: Injectable Hyaluronic Acid Hydrogel for Myocardial Repair
Journal: ACS Biomaterials Science & Engineering
Year: 2020, 6(12), pp. 6926–6937
Link: 🔗 Read Here
Citation Context: Widely cited in cardiac tissue regeneration research as a promising hydrogel-based therapy.

📄 4️⃣ Yang Jun, Xie Jinghui, Gao Chao, et al.
Title: VE-cad-Fc Functionalized Hyaluronic Acid Hydrogel
Journal: Journal of Tianjin University
Year: 2019, 52(1), pp. 33–39
Link: 🔗 Read Here
Citation Context: Referenced in biomaterial surface engineering papers for endothelial-friendly hydrogel design.

📄 5️⃣ Chao Gao, Yan Zhang, Jinghui Xie, et al.
Title: VE-cadherin functionalized injectable hydrogel promotes endothelial differentiation
Journal: Applied Materials Today
Year: 2020, Volume 20, Article 100690
Link: 🔗 Read Here
Citation Context: Frequently cited in angiogenesis hydrogel studies for vascular tissue engineering.

📄 6️⃣ Ke Xu, Chuanshun Zhu, Jinghui Xie, et al.
Title: Enhanced Vascularization of PCL Scaffolds through VEGF-Fc
Journal: Journal of Materials Chemistry B
Year: 2018, 6(6), p. 4485
Link: 🔗 Read Here
Citation Context: Referenced in scaffold vascularization research for improved angiogenic responses.

🏆 Conclusion

This researcher is highly suitable for a Best Researcher Award, particularly in biomaterials, regenerative medicine, and diabetic vascular disease research. Their combination of funded projects, impactful publications, and patents demonstrates innovation and leadership.

Jan Tesarik | Molecular Diagnostics | Excellence in Research

Published on by Molecular Biologist

Dr. Jan Tesarik | Molecular Diagnostics | Excellence in Research 

Dr. Jan Tesarik is a renowned Czech reproductive endocrinologist and embryologist, celebrated for his groundbreaking contributions to assisted reproductive technologies. He achieved the world’s first successful Gamete Intra-Fallopian Transfer (GIFT) in 1982, and later pioneered the first childbirths following oocyte fertilization with round spermatids (ROSI) and in-vitro cultured elongating spermatids (ELSI) in 1995 and 1998, respectively. In 2000, he developed an innovative nuclear transfer technique in mature human oocytes, now popularly known as the “3-parent-baby technique.” Dr. Tesarik has also advanced virtual imaging endoscopy methods and explored the beneficial effects of growth hormone on oocyte quality and uterine receptivity. Currently, he serves as the Director of the MARGen Clinic in Granada, Spain, and holds editorial positions in several esteemed journals. With over 400 scientific publications and more than 18,000 citations, his work continues to shape the field of reproductive medicine. researchgate.net

Professional Profile

Scopus

🎓 Education 

Dr. Tesarik obtained his MD degree in 1979 and his PhD in 1982 from the University of Prague. His early academic pursuits laid a strong foundation in reproductive biology, leading him to explore innovative techniques in human reproduction. His doctoral research focused on gamete physiology and early embryonic development, areas that would become central to his future breakthroughs. Throughout his academic journey, Dr. Tesarik demonstrated a commitment to integrating clinical practice with cutting-edge research, a philosophy that has guided his illustrious career.

💼 Experience 

Dr. Tesarik’s professional journey spans several decades and continents. After completing his education, he worked at Purkyne University in Brno, Czechoslovakia, where he began his pioneering research in reproductive medicine. In 1989, he joined the American Hospital of Paris, contributing to significant advancements in assisted reproductive technologies. Currently, he is the Director of the MARGen Clinic in Granada, Spain, where he continues to lead innovative research and clinical practices in reproductive health. His international experience has enriched his perspective, allowing him to integrate diverse methodologies and cultural approaches into his work.

🔬 Research Interests 

Dr. Tesarik’s research interests are deeply rooted in reproductive biology and embryology. He has extensively studied gamete physiology, fertilization processes, and early embryonic development. His work on the application of growth hormone in improving oocyte quality and uterine receptivity has opened new avenues in fertility treatments. Additionally, he has developed virtual imaging techniques, such as virtual hysteroscopy and salpingoscopy, enhancing non-invasive diagnostic capabilities in gynecology. In response to the COVID-19 pandemic, Dr. Tesarik investigated the effects of the virus on fertility and explored potential protective agents, including melatonin, to safeguard reproductive health during infections. researchgate.net

🏆 Awards 

Dr. Tesarik’s contributions to reproductive medicine have been recognized globally. Notably, he received the Silver Prize Award at the 1st International Congress of Perinatal Medicine in Tokyo, Japan, for his research on reproductive risks associated with consecutive abortions. His innovative techniques and clinical applications have earned him accolades from various medical societies and institutions. Beyond formal awards, his appointment as an Associate Editor in journals like Frontiers in Endocrinology and International Journal of Molecular Sciences reflects the high esteem in which his peers hold him. These honors underscore his enduring impact on the field of reproductive health.ecronicon.net

📚 Top Noted Publications 

Dr. Tesarik has an extensive publication record, with over 400 scientific articles and book chapters to his name. His works are widely cited, reflecting their significance in the field. Some of his notable publications include:

1. Endocrinology of Primary Ovarian Insufficiency: Diagnostic and Therapeutic Clues (2025)

This article provides a comprehensive overview of Primary Ovarian Insufficiency (POI), discussing its endocrinological aspects, diagnostic challenges, and potential therapeutic approaches. It emphasizes the importance of early detection and individualized treatment strategies to manage POI effectively.

2. Editorial: Growth Hormone in Fertility and Infertility: Physiology, Pathology, Diagnosis and Treatment, Volume II (2024)

This editorial summarizes recent findings on the role of growth hormone (GH) in female fertility and infertility. It discusses GH’s mechanisms of action in the reproductive system and explores its therapeutic potential in enhancing fertility outcomes, particularly in assisted reproductive technologies. frontiersin.org+2frontiersin.org+2researchgate.net+2

3. Mitochondria in Human Fertility and Infertility (2023)

Conclusion

Dr. Jan Tesarik’s career reflects exceptional innovation, longevity, and global impact in reproductive medicine and related biomedical sciences. His pioneering procedures (GIFT, ROSI, ELSI, nuclear transfer) and diagnostic tools place him among the leading figures in the field. While there is room to highlight collaborative and funding leadership more explicitly, the depth, originality, and translational success of his work strongly support his candidacy for a Research for Excellence Award.

Jin-Ju Lei | Molecular Diagnostics | Best Researcher Award

Published on by Molecular Biologist

Dr. Jin-Ju Lei | Molecular Diagnostics | Best Researcher Award 

Doctorate, at Renmin Hospital of Wuhan University, China.

Dr. Jin-Ju Lei is a dedicated and innovative medical doctor currently serving at the Cancer Center of Renmin Hospital, Wuhan University. A pioneer in the development of non-invasive pathological testing for cancer, Dr. Lei has combined her clinical expertise with cutting-edge biomedical research. Her career spans from foundational clinical training to advanced oncology specialization, demonstrating a consistent commitment to improving cancer diagnostics and treatment. Her contributions to oncological research have earned her recognition both in China and internationally, particularly for her work on metastasis mechanisms and cancer biomarkers. With over a decade of experience, she has played an active role in shaping modern cancer diagnostics and remains passionate about translating science into meaningful clinical outcomes. 🌱🔍

Professional Profile

Scopus

🎓 Education

Dr. Lei’s educational foundation was built at Xinxiang Medical University, where she earned her Bachelor’s degree in Clinical Medicine (2005–2010). She pursued advanced medical training and specialization at the prestigious Sun Yat-sen University Cancer Center, obtaining her Doctorate in Oncology (2010–2015). During this period, she received intensive clinical and research training in oncology, with a focus on cancer pathophysiology, molecular diagnostics, and precision medicine. 📚 Her academic path shaped her scientific curiosity, leading to a career that bridges patient care and translational cancer research. The rigorous programs at both institutions enabled her to build a strong command of oncology at both theoretical and applied levels. 🧠📖

🏥 Experience

Dr. Jin-Ju Lei has been serving at the Cancer Center, Renmin Hospital of Wuhan University since 2015. She started as a Resident Doctor (2015–2016) and was quickly promoted to Attending Physician in December 2016, a role she continues to fulfill with excellence. In her clinical duties, she specializes in managing complex cancer cases and developing diagnostic protocols using molecular technologies. Her clinical insight is further supported by her active engagement in research, where she explores novel biomarkers and treatment modalities. 👩‍⚕️ Her long-term experience in a leading hospital has allowed her to contribute to multi-disciplinary teams and collaborative studies, improving cancer detection and patient outcomes. 🔍💼

🧪 Research Interests

Dr. Lei’s research is centered on cancer biomarkers, metastasis mechanisms, and non-invasive diagnostics, particularly in breast, nasopharyngeal, and pancreatic cancers. 🧬 She has played a pivotal role in identifying the suppressive roles of proteins like NOP14 and the prognostic value of unconjugated bilirubin in cancer progression. Her interests also extend to liquid biopsy technologies, where she contributes to innovations like targeting nanoprobes for mRNA detection in circulating malignant cells. Her research aims to enable earlier, safer, and more accurate detection of cancers, ultimately reducing the burden of invasive procedures. Her interdisciplinary approach combines clinical insight with molecular and translational research. 🧫🧠

🏆 Awards

Although not explicitly listed, Dr. Lei’s career demonstrates the hallmarks of a high-achieving medical researcher. Her contributions to SCIE-indexed journals, her co-authorship in influential studies on cancer suppression and diagnostic biomarkers, and her role in developing innovative cancer testing methods position her as a likely nominee for awards in translational medicine, oncology, and medical innovation. 🏅 Her participation in international research collaborations, peer-reviewed publications, and breakthroughs in non-invasive cancer diagnostics signify her impactful role in the field. She is an ideal candidate for award nominations recognizing excellence in medical innovation and cancer research. 🌟

📚Top Noted Publications

Dr. Jin-Ju Lei has co-authored numerous peer-reviewed publications, reflecting her depth of involvement in translational oncology:

  • NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway
    Oncotarget, 2015.

    • Impact: Cited by 120+ articles.

    • Summary: Identified NOP14 as a tumor suppressor gene in breast cancer via inhibition of the NRIP1/Wnt/β-catenin signaling pathway.

    • Contribution: Advanced molecular understanding of breast cancer progression and potential therapeutic targets.

  • Unconjugated Bilirubin as a Prognostic Biomarker for Nasopharyngeal Carcinoma
    Cancer Prevention Research, 2016.

    • Impact: Cited by 90+ articles.

    • Summary: Demonstrated that elevated unconjugated bilirubin levels serve as a negative prognostic marker in nasopharyngeal carcinoma patients.

    • Contribution: Proposed a non-invasive and cost-effective biomarker for patient prognosis.

  • Exome sequencing reveals novel mutated genes in pancreatic cancer metastasis
    Cancer Biology & Therapy, 2012.

    • Impact: Cited by 110+ articles.

    • Summary: Used exome sequencing to uncover novel genetic mutations associated with pancreatic cancer metastasis.

    • Contribution: Provided a genomic basis for understanding metastatic behavior in pancreatic cancer.

  • HLA-G expression linked to prognosis in nasopharyngeal carcinoma
    International Journal of Biological Sciences, 2012.

    • Impact: Cited by 60+ articles.

    • Summary: Established a correlation between HLA-G overexpression and poor prognosis in nasopharyngeal carcinoma.

    • Contribution: Contributed to the field of immune evasion mechanisms in cancer.

  • MAGL promotes metastases in nasopharyngeal carcinoma
    International Journal of Clinical and Experimental Pathology, 2014.

    • Impact: Cited by 45+ articles.

    • Summary: Showed that monoacylglycerol lipase (MAGL) enhances metastatic potential in nasopharyngeal carcinoma.

    • Contribution: Linked lipid metabolism enzymes to tumor aggressiveness.

  • Autophagic cell death and radiation sensitization in hepatocellular carcinoma
    World Journal of Gastroenterology, 2017.

    • Impact: Cited by 30+ articles.

    • Summary: Explored autophagic mechanisms that sensitize hepatocellular carcinoma cells to radiation therapy.

    • Contribution: Suggested potential targets to enhance radiotherapy efficacy.

  • First primary cancer patients with second cancer: a population study
    Clinical and Experimental Medicine, 2023.

    • Impact: Rising citations in epidemiological research.

    • Summary: Analyzed population-level data on patients developing second primary cancers.

    • Contribution: Informs cancer surveillance and survivorship care strategies.

  • Innovative treatment for metastatic thyroid-like follicular carcinoma
    Frontiers in Oncology, 2024.

    • Impact: Emerging relevance in rare cancer treatment literature.

    • Summary: Presented a novel therapeutic approach for a rare metastatic renal carcinoma.

    • Contribution: Pioneered strategies in precision oncology for underrepresented cancers.

  • Blood biopsy using nanoprobe for lung cancer mRNA biomarkers
    Applied Physics Reviews, 2025.

    • Impact: High novelty and technological impact.

    • Summary: Developed a nanoprobe-based blood biopsy method for detecting mRNA biomarkers in lung cancer.

    • Contribution: Integrates nanotechnology with non-invasive cancer diagnostics.

Conclusion

Dr. Jin-Ju Lei is an exceptional candidate for the Research for Best Researcher Award. Her unparalleled expertise in clinical oncology, her innovative contributions to non-invasive cancer diagnostics, and her consistent track record of impactful research publications all underscore her suitability for this prestigious recognition. By further expanding her interdisciplinary collaborations and focusing on translational research, Dr. Lei can continue to lead the way in advancing cancer research and treatment.